ZA200207849B - Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response. - Google Patents
Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response. Download PDFInfo
- Publication number
- ZA200207849B ZA200207849B ZA200207849A ZA200207849A ZA200207849B ZA 200207849 B ZA200207849 B ZA 200207849B ZA 200207849 A ZA200207849 A ZA 200207849A ZA 200207849 A ZA200207849 A ZA 200207849A ZA 200207849 B ZA200207849 B ZA 200207849B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- prebiotic
- substance
- use according
- inulin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 70
- 235000013406 prebiotics Nutrition 0.000 title claims description 37
- 230000028993 immune response Effects 0.000 title description 13
- 238000009472 formulation Methods 0.000 title description 10
- 150000001720 carbohydrates Chemical class 0.000 title description 6
- 239000002671 adjuvant Substances 0.000 title description 2
- 229920001202 Inulin Polymers 0.000 claims description 17
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 17
- 229940029339 inulin Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 201000005505 Measles Diseases 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 14
- 235000013336 milk Nutrition 0.000 claims description 11
- 239000008267 milk Substances 0.000 claims description 11
- 210000004080 milk Anatomy 0.000 claims description 11
- 239000006041 probiotic Substances 0.000 claims description 11
- 230000000529 probiotic effect Effects 0.000 claims description 11
- 235000018291 probiotics Nutrition 0.000 claims description 11
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 10
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 7
- 235000013339 cereals Nutrition 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229920002488 Hemicellulose Polymers 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 229920001221 xylan Polymers 0.000 claims description 5
- 150000004823 xylans Chemical class 0.000 claims description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 4
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 claims 6
- 239000013589 supplement Substances 0.000 claims 6
- 241000186660 Lactobacillus Species 0.000 claims 3
- 241000194017 Streptococcus Species 0.000 claims 3
- 235000013351 cheese Nutrition 0.000 claims 3
- 235000015140 cultured milk Nutrition 0.000 claims 3
- 229940039696 lactobacillus Drugs 0.000 claims 3
- 239000006194 liquid suspension Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 235000013618 yogurt Nutrition 0.000 claims 3
- 235000015243 ice cream Nutrition 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 1
- 238000002255 vaccination Methods 0.000 description 9
- 235000016709 nutrition Nutrition 0.000 description 8
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 5
- 229940107187 fructooligosaccharide Drugs 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000003319 supportive effect Effects 0.000 description 4
- 108010010256 Dietary Proteins Proteins 0.000 description 3
- 102000015781 Dietary Proteins Human genes 0.000 description 3
- 235000021245 dietary protein Nutrition 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229940041323 measles vaccine Drugs 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000019904 Raftiline® Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Confectionery (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Jellies, Jams, And Syrups (AREA)
- Grain Derivatives (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00200735 | 2000-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200207849B true ZA200207849B (en) | 2003-12-30 |
Family
ID=8171132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200207849A ZA200207849B (en) | 2000-03-01 | 2002-09-30 | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response. |
Country Status (22)
Country | Link |
---|---|
US (2) | US20030040492A1 (es) |
EP (1) | EP1261355B1 (es) |
JP (1) | JP4838477B2 (es) |
KR (1) | KR20020081375A (es) |
CN (1) | CN1243551C (es) |
AR (1) | AR027968A1 (es) |
AT (1) | ATE283697T1 (es) |
AU (2) | AU3174601A (es) |
BR (1) | BR0108828A (es) |
CA (1) | CA2400969C (es) |
DE (1) | DE60107544T2 (es) |
ES (1) | ES2232591T3 (es) |
HK (1) | HK1051650A1 (es) |
HU (1) | HUP0204546A3 (es) |
IL (1) | IL151280A0 (es) |
MX (1) | MXPA02008447A (es) |
NO (1) | NO20024011D0 (es) |
PL (1) | PL365136A1 (es) |
PT (1) | PT1261355E (es) |
UA (1) | UA73763C2 (es) |
WO (1) | WO2001064225A1 (es) |
ZA (1) | ZA200207849B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7029702B2 (en) * | 1998-07-07 | 2006-04-18 | Ritter Natural Sciences Llc | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
US6319252B1 (en) | 1999-07-23 | 2001-11-20 | Mcdevitt Dennis | System and method for attaching soft tissue to bone |
KR20020043078A (ko) * | 2000-12-01 | 2002-06-08 | 한인규 | 올리고당이 포함된 복합생균제 |
GB0229015D0 (en) | 2002-12-12 | 2003-01-15 | Novartis Nutrition Ag | New Compound |
PT1638416E (pt) * | 2003-06-23 | 2013-07-08 | Nestec Sa | Utilização de uma fórmula nutricional para função de barreira intestinal óptima |
US20050118299A1 (en) * | 2003-12-01 | 2005-06-02 | The Iams Company | Companion animal compositions comprising short chain oligofructose |
US20050119222A1 (en) | 2003-12-01 | 2005-06-02 | The Iams Company | Compositions comprising fermentable fiber which are adapted for use by a companion animal and kits and methods of their use |
US20050118234A1 (en) * | 2003-12-01 | 2005-06-02 | The Iams Company | Methods and kits related to administration of a fructooligosaccharide |
NO320546B1 (no) * | 2003-12-12 | 2005-12-19 | Nova Biotics As | Prebiotiske kombinasjonsprodukter |
WO2006012536A2 (en) * | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
US7572474B2 (en) | 2005-06-01 | 2009-08-11 | Mead Johnson Nutrition Company | Method for simulating the functional attributes of human milk oligosaccharides in formula-fed infants |
US8287931B2 (en) | 2005-06-30 | 2012-10-16 | Mead Johnson Nutrition Company | Nutritional composition to promote healthy development and growth |
US8075934B2 (en) * | 2008-10-24 | 2011-12-13 | Mead Johnson Nutrition Company | Nutritional composition with improved digestibility |
JP4889262B2 (ja) * | 2005-08-19 | 2012-03-07 | 理研ビタミン株式会社 | 脂溶性薬剤組成物 |
US20080003329A1 (en) * | 2006-06-30 | 2008-01-03 | Ricardo Rueda | Enriched infant formulas |
EP2073643A2 (en) * | 2006-10-18 | 2009-07-01 | DSMIP Assets B.V. | Encapsulation of heat and moisture sensitive substances |
DE102007008664B4 (de) * | 2007-02-20 | 2021-07-29 | Vitacare Gmbh & Co. Kg | Mittel zur Anwendung bei Fructoseintoleranz |
EP2187756A1 (en) * | 2007-08-24 | 2010-05-26 | Barry Callebaut AG | Process and confectionery product produced thereby |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
CN102123715B (zh) | 2008-06-13 | 2014-12-17 | N.V.努特里奇亚 | 刺激免疫系统的营养物 |
US20110189148A1 (en) * | 2008-06-25 | 2011-08-04 | Ritter Pharmaceuticals, Inc. | Lactose compositions with decreased lactose content |
US8986769B2 (en) * | 2008-10-24 | 2015-03-24 | Mead Johnson Nutrition Company | Methods for preserving endogenous TGF-β |
US8425955B2 (en) | 2009-02-12 | 2013-04-23 | Mead Johnson Nutrition Company | Nutritional composition with prebiotic component |
CA2984935C (en) | 2009-02-24 | 2021-01-12 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US8293264B2 (en) * | 2009-05-11 | 2012-10-23 | Mead Johnson Nutrition Company | Nutritional composition to promote healthy development and growth |
WO2010143940A1 (en) | 2009-06-12 | 2010-12-16 | N.V. Nutricia | Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages |
EP3342413B1 (en) | 2009-07-15 | 2021-10-20 | N.V. Nutricia | Fucosyllactose as breast milk identical non-digestible oligosaccharide for treating and/or preventing viral diarrhoea |
US20120178674A1 (en) | 2009-07-15 | 2012-07-12 | N.V. Nutricia | Mixture of non-digestible oligosaccharides for stimulating the immune system |
WO2011060123A1 (en) | 2009-11-12 | 2011-05-19 | Nestec S.A. | Nutritional composition for promoting gut microbiota balance and health |
EP3202406A1 (en) | 2010-04-28 | 2017-08-09 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
US20110293784A1 (en) | 2010-05-28 | 2011-12-01 | Anja Wittke | Milk-based nutritional compositions |
NL2007268C2 (en) | 2011-08-16 | 2013-02-19 | Friesland Brands Bv | Nutritional compositions comprising human milk oligosaccharides and uses thereof. |
WO2013149017A1 (en) * | 2012-03-28 | 2013-10-03 | Kansas State University Research Foundation | Vaccine adjuvant |
WO2013187755A1 (en) | 2012-06-14 | 2013-12-19 | N.V. Nutricia | Fermented infant formula with non digestible oligosaccharides |
CN103330935A (zh) * | 2013-06-17 | 2013-10-02 | 中山大学 | 果糖作为疫苗佐剂的应用 |
CN107921058B (zh) * | 2015-08-04 | 2021-04-16 | 南方糖业股份公司 | 菊糖对鼻窦炎的预防作用 |
WO2019031961A1 (en) | 2017-08-11 | 2019-02-14 | N.V. Nutricia | OLIGOSACCHARIDE OF HUMAN MILK TO IMPROVE PHYSICAL IMMUNE CONDITION |
WO2019051381A1 (en) * | 2017-09-08 | 2019-03-14 | Evelo Biosciences, Inc. | EXTRACELLULAR VESICLES FROM PREVOTELLA |
TWI814739B (zh) | 2017-09-08 | 2023-09-11 | 美商艾弗洛生物科技股份有限公司 | 細菌胞外囊泡 |
JP7469037B2 (ja) * | 2019-02-28 | 2024-04-16 | 森永乳業株式会社 | 発酵乳 |
CN111529703B (zh) * | 2020-06-17 | 2023-09-15 | 湖南循天然营养有限公司 | 一种组合物及其制备方法与在制备免疫佐剂中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247071B1 (en) | 1985-10-31 | 1993-09-22 | The Australian National University | Immunotherapeutic treatment |
US5422346A (en) | 1988-01-06 | 1995-06-06 | California Natural Products | Instant dried dahlia inulin juice and its method of production and usage |
DE4341780A1 (de) * | 1993-12-08 | 1995-06-14 | Suedzucker Ag | Hydrierte Fructooligosaccharide |
DE69520528T2 (de) * | 1994-06-14 | 2001-09-27 | Raffinerie Tirlemontoise, S.A. | Verwendung einer Zusammensetzung enthaltend Inulin oder Oligofructose als Antikrebsmittel |
ATE169456T1 (de) * | 1996-12-23 | 1998-08-15 | Sitia Yomo Spa | Lyophilisierte, lebende bakerien enthaltende nahrungszusammensetzung |
US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
-
2001
- 2001-02-14 KR KR1020027011308A patent/KR20020081375A/ko not_active Application Discontinuation
- 2001-02-14 PL PL01365136A patent/PL365136A1/xx unknown
- 2001-02-14 AU AU3174601A patent/AU3174601A/xx active Pending
- 2001-02-14 DE DE60107544T patent/DE60107544T2/de not_active Expired - Lifetime
- 2001-02-14 UA UA2002097766A patent/UA73763C2/uk unknown
- 2001-02-14 ES ES01903767T patent/ES2232591T3/es not_active Expired - Lifetime
- 2001-02-14 PT PT01903767T patent/PT1261355E/pt unknown
- 2001-02-14 JP JP2001563122A patent/JP4838477B2/ja not_active Expired - Fee Related
- 2001-02-14 WO PCT/EP2001/001627 patent/WO2001064225A1/en active IP Right Grant
- 2001-02-14 EP EP01903767A patent/EP1261355B1/en not_active Expired - Lifetime
- 2001-02-14 AT AT01903767T patent/ATE283697T1/de not_active IP Right Cessation
- 2001-02-14 IL IL15128001A patent/IL151280A0/xx unknown
- 2001-02-14 BR BR0108828-9A patent/BR0108828A/pt not_active Application Discontinuation
- 2001-02-14 HU HU0204546A patent/HUP0204546A3/hu unknown
- 2001-02-14 CA CA2400969A patent/CA2400969C/en not_active Expired - Fee Related
- 2001-02-14 MX MXPA02008447A patent/MXPA02008447A/es active IP Right Grant
- 2001-02-14 CN CNB018058973A patent/CN1243551C/zh not_active Expired - Fee Related
- 2001-02-14 AU AU2001231746A patent/AU2001231746C1/en not_active Ceased
- 2001-03-01 AR ARP010100985A patent/AR027968A1/es not_active Application Discontinuation
-
2002
- 2002-08-22 NO NO20024011A patent/NO20024011D0/no unknown
- 2002-08-26 US US10/228,722 patent/US20030040492A1/en not_active Abandoned
- 2002-09-30 ZA ZA200207849A patent/ZA200207849B/en unknown
-
2003
- 2003-06-02 HK HK03103906A patent/HK1051650A1/xx not_active IP Right Cessation
-
2004
- 2004-04-13 US US10/822,799 patent/US7101553B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1243551C (zh) | 2006-03-01 |
JP4838477B2 (ja) | 2011-12-14 |
HUP0204546A3 (en) | 2003-10-28 |
US20040191234A1 (en) | 2004-09-30 |
CA2400969A1 (en) | 2001-09-07 |
NO20024011L (no) | 2002-08-22 |
PL365136A1 (en) | 2004-12-27 |
AU2001231746B2 (en) | 2004-12-23 |
US20030040492A1 (en) | 2003-02-27 |
WO2001064225A1 (en) | 2001-09-07 |
MXPA02008447A (es) | 2002-12-13 |
AU3174601A (en) | 2001-09-12 |
US7101553B2 (en) | 2006-09-05 |
AR027968A1 (es) | 2003-04-16 |
PT1261355E (pt) | 2005-02-28 |
CN1422158A (zh) | 2003-06-04 |
BR0108828A (pt) | 2002-12-10 |
AU2001231746C1 (en) | 2005-10-06 |
NO20024011D0 (no) | 2002-08-22 |
DE60107544D1 (de) | 2005-01-05 |
HUP0204546A2 (en) | 2003-05-28 |
HK1051650A1 (en) | 2003-08-15 |
JP2003533438A (ja) | 2003-11-11 |
ES2232591T3 (es) | 2005-06-01 |
DE60107544T2 (de) | 2005-12-15 |
EP1261355B1 (en) | 2004-12-01 |
CA2400969C (en) | 2011-04-19 |
EP1261355A1 (en) | 2002-12-04 |
ATE283697T1 (de) | 2004-12-15 |
KR20020081375A (ko) | 2002-10-26 |
UA73763C2 (en) | 2005-09-15 |
IL151280A0 (en) | 2003-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001231746B2 (en) | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response | |
AU2001231746A1 (en) | Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response | |
JP4456329B2 (ja) | 炎症過程及び非特異的免疫パラメータの異常活性化を減少させるためのプレバイオティクスを含む組成物 | |
JP4738717B2 (ja) | 乳酸菌からのリポテイコ酸、およびグラム陰性菌、潜在的病原性グラム陽性菌によって媒介される免疫応答を調節するためのその使用 | |
CN113662199A (zh) | 用于预防胃肠道损伤和/或促进胃肠道愈合的人乳寡糖 | |
CZ2003535A3 (cs) | Potravinářský prostředek | |
TWI639387B (zh) | 用於預防胃腸道受傷及/或促進胃腸道治癒之半乳寡糖 | |
TW201729824A (zh) | 用於促進腸道屏障功能並減緩內臟疼痛之營養組成物 | |
Angus et al. | Prebiotic ingredients with emphasis on galacto‐oligosaccharides and fructo‐oligosaccharides | |
JP4064515B2 (ja) | Il−12産生誘導組成物 | |
JPWO2016136624A1 (ja) | 免疫調節剤及びその用途 | |
WO2003063886A1 (fr) | Inhibiteur d'adhesion d'helicobacter pylori | |
KR101985644B1 (ko) | 면역 증진제 및 이를 포함하는 면역 개선용 음식품 조성물 | |
García-Elorriaga et al. | Nutrition and intestinal microflora | |
US20220400729A1 (en) | Synergistic combination of butyric-acid-producing prebiotics and probiotics | |
CN106974940B (zh) | 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用 | |
Boehm et al. | Carbohydrates in human milk and infant formulas | |
Eseceli | Pro-/Anti-Inflammatory Food Supplements: Probiotics and Prebiotics | |
EP4081225A1 (en) | Uses of lipoteichoic acid from bifidobacteria |